Affirm AFRM 深 沪
等待开盘 01-13 09:30:00 美东时间
77.69
-4.110
-5.02%
华盛通- 最 高84.65
- 今 开83.90
- 成交量 733.17万股
- 最 低 75.25
- 昨 收 81.80
- 总市值 256.38亿
- 52周最高 100.00
- 市盈率 静 507.78
- 换手率 2.22%
- 52周最低 30.901
- 委 比 -71.31%
- 总股本 3.30亿
- 历史最高 176.65
- 量 比 4.63
- 振 幅 11.49%
- 历史最低 8.62
- 每 手 1
- 风险率 12.63%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多特朗普拟议信用卡利率上限致银行股下挫
在特朗普总统呼吁将信用卡年利率上限设为10%并维持一年后，第一资本（COF）、花旗集团（C）、摩根大通（JPM）、美国银行（BAC）、Visa（V）、万事达...
01-12 23:34
特朗普炮轰信用卡利率 美国银行股应声大跌
美国总统唐纳德・特朗普称，若贷款机构无视其要求、不将信用卡年利率上限设定为10%并维持一年，便属违法行为。此番言论发布后，旗下拥有信用卡业务的美国银行股在盘...
01-12 20:55
快讯 | Klarna Group上涨6.5%，Affirm上涨4%，Block上涨2.4%，Sezzle上涨4.3%
Klarna Group up 6.5%, Affirm up 4%, Block up 2.4%, Sezzle up 4.3%
01-12 20:04
Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Unaudited)
Biodesix, Inc. reported preliminary financial results for Q4 and FY 2025, with estimated revenue of $28.8M (41% YOY growth) for Q4 and $88.5M (24% YOY growth) for the full year. Lung Diagnostics revenue grew 47% and 22% for Q4 and FY 2025, respectively, driven by increased test volumes and reimbursement. Development Services revenue increased 13% and 41% for Q4 and FY 2025. Cash and cash equivalents reached $19.0M as of December 31, 2025, a 14% i...
01-12 11:00
美股大行评级 | 潜在涨幅197.4%！奥麦罗制药获HC Wainwright升目标价至40美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持奥麦罗制药"买入"评级，目标价从20美元升至40美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从26美元升至27美元
01-09 20:22
A Look Into Affirm Holdings Inc's Price Over Earnings
In the current session, the stock is trading at $83.00, after a 0.80% spike. Ov...
01-08 02:00
Is Affirm's Rival Buy Now, Pay Later Stock Now A Value Pick Following Its 60% Pullback? Value Score Surges
Once one of the market's hottest BNPL names, Sezzle, has tumbled roughly 60% in less than half a year.
01-07 17:30
Kamada Provides 2026 Annual Guidance of $200 - $205 Million in Revenues and $50 - $53 Million of Adjusted EBITDA, Representing Double-Digit Growth and Affirms 2025 Financial Guidance
Kamada Ltd. forecasts 2026 revenues of $200-$205 million and adjusted EBITDA of $50-$53 million, reflecting 13% and 23% increases respectively from 2025 mid-point guidance. Growth is driven by organic expansion of its commercial product portfolio, including U.S. sales and ex-U.S. sales of key products like KAMRAB® and GLASSIA®. The company also prioritizes M&A and business development to enhance its product portfolio and long-term growth. Kamada ...
01-07 12:00
3 Stocks to Sell in 2026
The stock market, buoyed by the U.S. government’s removal of Venezuelan President Nicholas Maduro, is off to a good start in 2026, with the S&P 500 up 1.3% in the first week of trading.
01-07 05:16
Consumer finance stocks gain over holiday shopping season
A strong holiday shopping season spurred most consumer finance stocks higher in the past month, with many credit card, Buy Now, Pay Later, and fintech app stocks outperforming the S&P 500's 4.5% incre...
2025-12-24 01:28
